Influenza is a disease of public health importance due to the substantial seasonal morbidity and mortality and the high pandemic potential of its aetiologic agents, influenza viruses. Diagnosis of influenza is mainly based on laboratory testing (i.e. molecular testing) of nasopharyngeal samples....

The end of 2019 saw the emergence of a novel severe acute respiratory syndrome: coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19). As of December 2023, eight vaccines (Comirnaty, Spikevax, Vaxzevria, Jcovden Valneva, Nuvaxovid, VidPrevtyn, and Bimervax) have been...

This core protocol for ECDC studies of VE against hospitalisation with severe acute respiratory infection (SARI) laboratory-confirmed with SARS-CoV-2 or with influenza, version 4.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine...

The end of 2019 saw the emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19). As of October 2023, almost 276 million cases and more than 2.2 million deaths had been reported in the WHO European Region [1]. As of October...

This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries. This work is performed within the Vaccine Effectiveness, Burden and...

This document presents the core protocol for ECDC studies of CVE and IVE against symptomatic laboratoryconfirmed influenza or SARS-CoV-2 infection, respectively, at primary care level. This core protocol presents the main elements for a multicentre (multi-country) study of IVE/CVE at primary...

This core protocol for ECDC studies of vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or with influenza, version 2.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine...

This protocol presents a common methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating EU/EEA Member States. This work is performed within the Vaccine Effectiveness, Burden and Impact Studies (VEBIS) framework contract. A pilot...

The end of 2019 saw the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19). By early August 2022, over 160 million cases and over one million deaths had been reported in the European Union/European Economic Area...

The overall aim of the study is to monitor near real-time performance of COVID-19 vaccines administered as part of 2023 autumnal vaccination campaigns in the community-dwelling resident population aged ≥65 years in EU/EEA countries to detect any variation in VE, so that public health vaccine...